Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022

We assessed the protection conferred by naturally-acquired, vaccine-induced and hybrid immunity during the concomitant Omicron and Delta epidemic waves in France on symptomatic infection and severe COVID-19. The greatest levels of protection against both variants were provided by hybrid immunity. Pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Suarez Castillo, Milena, Khaoua, Hamid, Courtejoie, Noémie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2022
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027152/
https://www.ncbi.nlm.nih.gov/pubmed/35451363
http://dx.doi.org/10.2807/1560-7917.ES.2022.27.16.2200250
_version_ 1784691289417056256
author Suarez Castillo, Milena
Khaoua, Hamid
Courtejoie, Noémie
author_facet Suarez Castillo, Milena
Khaoua, Hamid
Courtejoie, Noémie
author_sort Suarez Castillo, Milena
collection PubMed
description We assessed the protection conferred by naturally-acquired, vaccine-induced and hybrid immunity during the concomitant Omicron and Delta epidemic waves in France on symptomatic infection and severe COVID-19. The greatest levels of protection against both variants were provided by hybrid immunity. Protection against Omicron symptomatic infections was systematically lower and waned at higher speed than against Delta in those vaccinated. In contrast, there were little differences in variant-specific protection against severe inpatient outcomes in symptomatic individuals.
format Online
Article
Text
id pubmed-9027152
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher European Centre for Disease Prevention and Control (ECDC)
record_format MEDLINE/PubMed
spelling pubmed-90271522022-05-03 Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022 Suarez Castillo, Milena Khaoua, Hamid Courtejoie, Noémie Euro Surveill Rapid Communication We assessed the protection conferred by naturally-acquired, vaccine-induced and hybrid immunity during the concomitant Omicron and Delta epidemic waves in France on symptomatic infection and severe COVID-19. The greatest levels of protection against both variants were provided by hybrid immunity. Protection against Omicron symptomatic infections was systematically lower and waned at higher speed than against Delta in those vaccinated. In contrast, there were little differences in variant-specific protection against severe inpatient outcomes in symptomatic individuals. European Centre for Disease Prevention and Control (ECDC) 2022-04-21 /pmc/articles/PMC9027152/ /pubmed/35451363 http://dx.doi.org/10.2807/1560-7917.ES.2022.27.16.2200250 Text en This article is copyright of the authors or their affiliated institutions, 2022. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.
spellingShingle Rapid Communication
Suarez Castillo, Milena
Khaoua, Hamid
Courtejoie, Noémie
Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022
title Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022
title_full Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022
title_fullStr Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022
title_full_unstemmed Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022
title_short Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022
title_sort vaccine-induced and naturally-acquired protection against omicron and delta symptomatic infection and severe covid-19 outcomes, france, december 2021 to january 2022
topic Rapid Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027152/
https://www.ncbi.nlm.nih.gov/pubmed/35451363
http://dx.doi.org/10.2807/1560-7917.ES.2022.27.16.2200250
work_keys_str_mv AT suarezcastillomilena vaccineinducedandnaturallyacquiredprotectionagainstomicronanddeltasymptomaticinfectionandseverecovid19outcomesfrancedecember2021tojanuary2022
AT khaouahamid vaccineinducedandnaturallyacquiredprotectionagainstomicronanddeltasymptomaticinfectionandseverecovid19outcomesfrancedecember2021tojanuary2022
AT courtejoienoemie vaccineinducedandnaturallyacquiredprotectionagainstomicronanddeltasymptomaticinfectionandseverecovid19outcomesfrancedecember2021tojanuary2022

Ejemplares similares